Refine by
Advanced Prostate Cancer Suppliers & Manufacturers
8 companies found
based inMississauga, ONTARIO (CANADA)
Profound Medical develops customizable, incision-free therapies which combine real-time Magnetic Resonance (MR) imaging, thermal ultrasound and closed-loop temperature feedback control for the radiation-free ablation of diseased ...
based inWoodinville, WASHINGTON (USA)
Cancer Targeted Technology is designing and patenting small molecular weight enzyme inhibitors with unique and exceptional imaging and drug delivery properties. Cancer Targeted Technology (CTT) develops innovative targeted agents for cancer that ...
CTT1057 is an innovative 18F-labeled PET agent for prostate cancer that can be imaged within 2 hours of administration. CTT1057 will specifically and sensitively detect cancer that has escaped from the prostate as well as distant metastatic disease ...
based inSaint-Prex, SWITZERLAND
Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group committed to helping people around the world build families and live better lives. Ferring is a leader in reproductive medicine and maternal health, and in specialty ...
FIRMAGON® (degarelix) is a treatment for men with advanced hormone-dependent prostate cancer. It has a novel mechanism of action that is different from traditional LHRH agonist therapy commonly ...
based inMonmouth Junction, NEW JERSEY (USA)
MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet ...
Histrelin acetate, a GnRH analogue, is a GnRH Receptor agonist. Histrelin acetate increases serum luteinising hormone (LH), follicle stimulating hormone (FSH) and testosterone levels. Histrelin acetate can be used in the research of prostate cancer, ...
based inCarlton, AUSTRALIA
Radiopharm Theranostics has the ambition to become a recognised leader in the development of radiopharmaceutical products for both diagnostic and therapeutic uses in areas of high unmet medical needs. There is unique potential of ...
PSA-mAb is the invention of Professor David Ulmert formerly of Memorial Sloan Kettering and now ...
based inLausanne, SWITZERLAND
Debiopharm is an independent biopharmaceutical company based in Switzerland with an ongoing commitment to improve patient outcomes and quality of life in oncology and bacterial infections. Our main activities include drug development, drug ...
Triptorelin decreases the serum testosterone to castrate levels (estradiol in females). Androgen deprivation stops the growth of the androgen dependent prostate cancer, alleviating pain and improving thus the ...
based inFranklin, TENNESSEE (USA)
Created by urologists for urologists, UroTech is the best way to use advanced medical technology: Avoid significant capital expenditures: Purchasing just one of the advanced technologies now available - much less the five offered by UroTech - would ...
Cryoablation is emerging as an effective, minimally invasive treatment for localized prostate cancer. Cryoablation is revolutionizing localized prostate cancer treatment by abolishing the "one shot" treatment method of having only one chance at ...
based inSolna, SWEDEN
Vivesto AB is a specialty pharmaceutical company focused on thedevelopment of new therapeutic options for patients suffering from hard-to-treatcancers. It has an emerging pipeline of clinical-stage assets targeting late-stagecancers. Apealea® ...
Docetaxel micellar is a product candidate in early clinical development and is a novel formulation that combines XR-17 with docetaxel - a well-established cytotoxin, currently administered intravenously and containing ethanol. In June 2020, Vivesto ...